Remarkable Effect of Gefitinib Retreatment in a Lung Cancer Patient With Lepidic Predominat Adenocarcinoma who had Experienced Favorable Results From Initial Treatment With Gefitinib: A Case Report.
Gefitnib is an oral agent of epidermal growth factor receptor tyrosine kinase inhibitor, and it has a certain efficacy against non-small cell lung cancer. There are some reports that the non-small cell lung cancer patients who experienced disease progression after responding to gefitinib were again sensitive to re-administration of gefitinib following temporary cessation of gefitinib. This is the case report showing a remarkable effect of gefitinib re-treatment in a patient with metastatic invasive adenocarinoma who had experienced favorable results from the initial treatment with gefitinib.
Department of Internal medicine, Collage of Medicine, Soonchunhyang University, Cheonan, Republic of Korea.
Su Jin
SJ
Lee
Ho Sung
HS
Lee
Jae Sung
JS
Choi
Ju Ock
JO
Na
Ki Hyun
KH
Seo
Mi Hye
MH
Oh
Sung Shick
SS
Jou